Organisation paid for research Program year 2025 Source: CMS Open Payments

Bliss Healthcare Services

Neither a doctor nor a teaching hospital

Research payments

$1,198,433

112 payments

Through program year 2025, Bliss Healthcare Services is reported as receiving $1,198,433 in research payments, across 112 payments.

By program year

7 rows

Year	Kind	Amount	Payments
2025	Research	$37,132	4
2024	Research	$33,981	13
2023	Research	$63,098	10
2022	Research	$87,039	14
2021	Research	$504,059	17
2020	Research	$377,332	40
2019	Research	$95,792	14

Breakdown

Who paid Research payments · program years 2019–2025

Merck Sharp & Dohme Corporation $613,244 36 payments
ViiV Healthcare Company $576,389 73 payments
GlaxoSmithKline, LLC. $8,800 3 payments

Studies the money was for Research payments · program years 2019–2025

A Phase 2,3, Randomized, Placebo-Controlled, Double-Blind Clinical Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of MK-4482 in Non-Hospitalized Adults with COVID-19. $426,692 8 payments
A Phase III, Randomized, Multicenter, Parallel-Group, Non-Inferiority $160,747 20 payments
A Phase 3, Randomized, Active-Controlled, Open-label Clinical Study to Evaluate a Switch to Doravirine,Islatravir DOR,ISL Once-Daily in Participants With HIV-1 Virologically Suppressed on Antiretroviral Therapy $152,359 8 payments
A Phase 3B Multi-Center, Open Label, Single Arm, 48-Week Study, Evalua $142,666 12 payments
A Phase III, Randomised, Double-Blind, Multicentre, Parallel-Group, No $132,835 11 payments
A Phase 4, Randomized, Open-Label, Two-Arm Study Evaluating Implementa $83,212 18 payments
Captivate (Cab la for Prep Utilization Outcomes Experience) $30,065 2 payments
PH 3 HIV Two-Year Non-Inferiority Compared to Standard of Care Safety/ $15,182 5 payments
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety and Tolerability, Efficacy, and Immunogenicity of V590 rVSV G-SARS-CoV-2-S, Live in Healthy Individuals 16 Years of Age or Older $10,500 1 payment
A Phase Iiib, Multi-Center, Non-Randomized, Parallel-Group, Open-Label $8,800 3 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.